Effect and Safety of a New Conditioning Regimen with Chidamide and BEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.01.017
- Author:
Sen LI
1
;
Jin-Jie GAO
1
;
Yan LI
1
;
Fei DONG
1
;
Qi-Hui LI
1
;
Wei ZHAO
1
;
Wei WAN
1
;
Ping YANG
1
;
Ji-Jun WANG
1
;
Hong-Mei JING
1
Author Information
1. Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
- Publication Type:Journal Article
- Keywords:
lymphoma;
conditioning regimen;
autologous hematopoietic stem cell transplantation;
chidamide
- MeSH:
Humans;
Hematopoietic Stem Cell Transplantation;
Transplantation Conditioning/methods*;
Transplantation, Autologous;
Retrospective Studies;
Aminopyridines/therapeutic use*;
Lymphoma/therapy*;
Benzamides/therapeutic use*;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Male;
Female;
Cytarabine/therapeutic use*;
Melphalan/therapeutic use*;
Adult;
Middle Aged;
Podophyllotoxin/therapeutic use*;
Carmustine;
Etoposide
- From:
Journal of Experimental Hematology
2025;33(1):121-126
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the efficacy and safety of a new conditioning regimen with chidamide and BEAM for autologous hematopoietic stem cell transplantation (AHSCT) in patients with lymphoma.
METHODS:Medical records and further follow-up data from 85 patients with lymphoma from May 2015 to September 2020 in our hospital were retrospectively collected and analyzed.
RESULTS:Among 85 patients, 52 cases accepted BEAM regimen and 33 cases accepted CBEAM followed by AHSCT. In CBEAM group, 18 patients (54.5%) received AHSCT as salvage therapy, while only 26.9% (14 cases) for salvage in BEAM group ( P < 0.01). CBEAM conditioning resulted in shorter neutrophil engraftment of 2 days, while no significant difference was found in platelet engraftment. Although the incidence of liver impairment was higher in CBEAM group (12.1%), the grade of impairment was only Ⅰ to Ⅱ. The two conditioning regimens both achieved good complete remission rate of over 90%, and no transplant-related death occurred. The median follow-up time in the CBEAM group was 18(12, 22) months, and 39(20, 59) months in the BEAM group. There were no significantly differences in 2-year progression-free survival (PFS) and overall survival (OS) rate between the two groups (P >0.05). In patients with refractory or relapsed non-Hodgkin lymphoma, the 2-year PFS rate after transplantation in BEAM group and CBEAM group was 74.1% and 92.9%, respectively (P >0.05), indicating that chidamide may have certain advantages in prolonging PFS.
CONCLUSION:CBEAM conditioning regimen has a good efficacy and safety in lymphoma patients before AHSCT, especially in refractory and relapsed non-Hodgkin lymphoma patients, suggesting that it could serve as an alternative conditioning regimen prior to AHSCT for lymphoma.
